A rare mutation that leads to high CREB3 activity is associated with a reduced risk of developing ALS and slower disease ...

TRE-515, a small molecule inhibitor of deoxycytidine kinase, is being developed for autoimmune diseases and in clinical ...

Trace is partnering with Unlearn as it advances plans for a clinical trial of its treatment candidate that targets the UNC13A ...

Edaravone may exert its neuroprotective effects in ALS by also correcting the abnormal localization of TDP-43, a key ...

Columnist Kristin Neva says a couple days in the Florida sunshine, away from the demands of caregiving, did wonders for her ...

Statin use does not affect survival outcomes for ALS patients, so there may be no need to stop taking them after a diagnosis, ...

Improvement may seem unlikely for people with ALS, but columnist Dagmar Munn shares how she's learned to set health goals — ...

SNUG01 is a first-in-class targeted gene therapy that’s designed to increase the levels of TRIM72, a protein with ...

The U.S. Food and Drug Administration approved treatment for 11 patients with the rare familial ALS caused by mutations in ...

NUZ-001 slowed respiratory declines in ALS patients in a Phase 1 trial, and Neurizon is working to ready it for the HEALEY ...

Certain subsets of immune NK cells were altered in the blood of people with ALS, and could serve as therapeutic targets, a ...

After her late husband's ALS diagnosis, columnist Juliet Taylor connected with other caregivers who provided support and ...